FDA 510(k) Glossary · pathway

Premarket Approval (PMA)

Premarket Approval (PMA) is the most stringent FDA regulatory pathway, required for Class III high-risk medical devices. Unlike the 510(k) pathway, PMA requires valid scientific evidence - typically from clinical trials - demonstrating that the device is safe and effective for its intended use.
Dataset Insight - 510k Database (166,200 records, 1980–2025)
PMA devices are not included in the 510k Database dataset. The dataset covers 510(k) clearances only. PMA-approved devices represent the high-risk Class III segment of the market.

Definition

Premarket Approval (PMA) is the FDA regulatory pathway under Section 515 of the Federal Food, Drug, and Cosmetic Act for Class III medical devices - those that support or sustain human life, are implanted in the body, or present a potential unreasonable risk of illness or injury. PMA is the most stringent type of device marketing application required by the FDA.

PMA vs 510(k)

Feature510(k) ClearancePMA Approval
Device classClass I/IIClass III
Evidence requiredSubstantial equivalence to predicateValid scientific evidence (clinical trials)
FDA decisionClearanceApproval
Review target90 days180 days
Predicate requiredYesNo

PMA Supplements

After PMA approval, any modification to an approved device requires a PMA Supplement - an additional submission demonstrating that the change does not affect safety or effectiveness. This is analogous to a new 510(k) for modifications to a cleared device, but within the PMA framework.

Relationship to 510(k) and De Novo

Manufacturers of novel devices that would otherwise default to Class III can seek De Novo classification to obtain Class II status if the device is of low-to-moderate risk. A successful De Novo avoids the PMA requirement and allows the device to be cleared through future 510(k) submissions.

FDA References

Related Terms

510(k) Premarket Notification - De Novo Classification - Device Classification - Substantial Equivalence

Frequently Asked Questions

Premarket Approval (PMA) is the FDA's most rigorous premarket review process, required for Class III medical devices - those that support or sustain human life, are implanted, or present unreasonable risk of injury. PMA requires the manufacturer to provide valid scientific evidence, typically from clinical trials, demonstrating the device's safety and effectiveness. Unlike 510(k) clearance, PMA results in an FDA approval, not just a clearance.

The key differences are: (1) Risk level - PMA is for Class III high-risk devices; 510(k) is primarily for Class II moderate-risk devices. (2) Evidence - PMA requires clinical trial data; 510(k) requires substantial equivalence to a predicate. (3) Standard - PMA results in approval (safety and effectiveness demonstrated); 510(k) results in clearance (substantially equivalent to predicate). (4) Timeline - PMA reviews typically take 180+ days; 510(k) targets 90 days.

PMA is required - not chosen - when a device is classified as Class III and no De Novo or other pathway is available. Common Class III devices requiring PMA include implantable cardiac devices (certain pacemakers, ICDs), cochlear implants, and certain Class III diagnostics. Manufacturers may avoid PMA by designing devices to fit Class II and using the 510(k) pathway.

Yes. The FDA can initiate a 'call for PMAs' for a Class III device type that was initially marketed under a 510(k) through a preamendment exemption. This process, sometimes called a 'down-classification' or 'PMA call', requires manufacturers to submit PMAs or stop marketing. This has occurred for specific implantable devices.